

The Manager Companies - ASX Limited
20 Bridge Street
Sydney NSW 2000

ASX Announcement
26 February 2026
(37 pages)

HALF YEARLY REPORT AND ACCCOUNTS

In accordance with Listing Rule 4.2A, I attach the Company's Appendix 4D and Interim Financial Report for the half year ended 31 December 2025. This Interim Financial Report should be read in conjunction with the Company's 30 June 2025 Annual Report.

Yours sincerely



Richard Edwards
Company Secretary

For personal use only



Appendix 4D

Half Year Report

Name of entity

ALPHA HPA LIMITED

ABN or equivalent company
reference

79 106 879 690

Financial year ended ('current period')

31 DECEMBER 2025

Results for announcement to the market

Revenues from ordinary activities	Up	270.9%	to	263,616
Loss from ordinary activities after tax attributable to members	Up	42.3%	to	22,538,525
Net loss for the period attributable to members	Up	42.3%	to	22,538,525
Dividends (distributions)		Amount per security		Franked amount per security
Final dividend		Nil¢		Nil¢
Interim dividend		Nil¢		Nil¢
Previous corresponding period				
Final dividend		Nil¢		Nil¢
Interim dividend		Nil¢		Nil¢
Record date for determining entitlements to the dividend.		N/A		
Brief explanation of any of the figures reported above and short details of any bonus or cash issue or other item(s) of importance not previously released to the market:				
NTA backing		Current period		Previous corresponding period
Net tangible asset backing per ordinary security		0.18 cents		0.20 cents

The attached Half Year Report which forms part of this Appendix 4D has been audited.

For personal use only

For personal use only



ABN 79 109 879 690

**Alpha HPA Limited
Interim Financial Report**

for the half-year ended 31 December 2025

Contents

Directors' Report.....	3
Lead Auditor's Independence Declaration	16
Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income	17
Condensed Consolidated Interim Statement of Financial Position	18
Condensed Consolidated Interim Statement of Changes in Equity	19
Condensed Consolidated Interim Statement of Cash Flows.....	20
Notes to the Condensed Consolidated Interim Financial Statements	21
Directors' Declaration	32
Independent Auditor's Review Report to the Shareholders of Alpha HPA Limited	33
Corporate Information.....	35

For personal use only

Directors' Report

The Directors of Alpha HPA Limited ('Alpha' or 'the Company') and its subsidiaries ('the Group') submit their report for the half-year ended 31 December 2025 and the Auditor's review report thereon.

Directors

The following persons were Directors of the Company during the reporting period and up to the date of this report:

Norman Seckold	Chairman
Robert Williamson	Managing Director
Rimas Kairaitis	Director and Chief Commercial Officer
Dr Regan Crooks	Non-Executive Director
Marghanita Johnson	Non-Executive Director
Annie Liu	Non-Executive Director
Anthony Sgro	Non-Executive Director

Results

The loss of the Group for the period after providing for income tax amounted to \$22,538,124 (2024 - loss of \$15,839,951).

Overview

Alpha is an ASX-listed specialty materials and technology company focused on the delivery and operation of the HPA First and Alpha Sapphire Projects in Queensland.

Each project represents the commercialisation of the Company's proprietary aluminium purification and refining technology and the production of critical high purity aluminium materials for a range of growing high technology sectors, including:

- Semiconductors;
- Lithium-ion batteries;
- Direct Lithium Extraction (DLE);
- Synthetic sapphire glass for sapphire optics, power-semiconductors, micro-LED technology; and
- Technical ceramics and specialty catalysts.

Alpha is in continuous production at its Gladstone based, HPA First Project Stage One (**Stage One**), producing the Company's full range of high purity aluminium materials at an annualised rate of +350 metric tonnes per annum (tpa) for the full product offering, which includes:

- High purity aluminas (**HPA**)
- High purity alumina hydroxides (**ATH**)
- High purity aluminium nitrate precursors (**Al-Nitrate**), and;
- High purity synthetic sapphire glass

At the same location, the Company is in construction of Stage Two of the HPA First Project (**Stage Two**). With an installed capacity of >10,000 metric tonnes per annum of all products, Stage Two will be the world's largest, single site manufacturing facility of high purity aluminium materials.

For personal use only

Directors' Report

Review of Operations

Highlights for the period include:

Stage Two HPA First Project (under construction)

- No recordable injuries on the project to date;
- Significant progress across critical workstreams for construction and delivery of Stage Two;
- Completion of bulk earthworks and commencement of civils;
- Site delivery of first large scale, offsite fabricated process equipment, including solvent extraction (SX) and Orica reagent tanks;
- First major Structural, Mechanical and Piping (**SMP**) installation contracts issued and SMP contractor mobilised; and
- Concrete works for initial Orica reagents and SX completed.

Product Marketing

- Continued demand growth from the semiconductor sector, with AI/data centres and power-semiconductors remaining the strongest demand points;
- Alpha's novel capability to deliver zero Uranium/Thorium content is driving thermal filler demand in the semiconductor sector;
- Conversion of Letter of Intent (**LOI**) into binding CY2026 supply contract to a South Korean customer for thermal fillers in HBM chip packaging;
- Further CY2026 supply contracts to Japanese customers under negotiation;
- Customer contracts under negotiation exceeded Stage One supply capacity;
- Surpassed monthly record for semiconductor sector shipments in December 2025;
- Fourth round qualification of sapphire wafers with leading power-semi manufacturer;
- SEMICON Japan confirms strong demand and pricing environment for Alpha's products;
- Strong results from early-stage outreach into fine ceramics/semiconductor tooling; and
- Product qualification and test work underway with approximately 120 separate end users.

Stage One HPA First Project (in production)

- Stage One safety performance remains strong with no recordable injuries reported for the period;
- Engineering advanced to unlock capacity Stage One production to meet CY2026-2027 demand; and
- Sales and inbound demand from the semiconductor sector for high purity alumina and hydroxides well above Stage One capacity.

Corporate

- Subsequent to period end, \$225 million, two tranche capital raising backed by \$75 million participation by the National Reconstruction Fund Corporation;
- Fully drawn \$30 million of corporate funding from QIC Critical Minerals and Battery Technology Fund; and
- Appointment of Peter Ware as Chief Operations Officer (COO) to lead the optimisation of Stage One and delivery of Stage Two.

HPA First Project – Stage One

Production

During the period, product sales continued to build from Stage One as Alpha consolidates its position as a reliable, high-quality supplier to the semiconductor sector.

End-applications serviced include:

- **Semiconductor Sector**
 - Thermal interface/thermal filler applications
 - Chemical Mechanical Planerization (**CMP**) polishing
 - Technical ceramics for semiconductor equipment components
 - Thermal/plasma sprays applications

For personal use only

Directors' Report

Production (continued)

- **Battery Sector**
 - Mesoporous aluminas for LiB anode coating
 - Al-Nitrates for LiB anode coating
 - Al-Nitrates for solid state electrolyte formulation
- **Other**
 - Alumina for hydrogen production
 - Gamma alumina for protein collection (pharmaceutical)
 - Technical ceramics
 - Amorphous ATH for DLE

Stage One production of Alpha's ultra-high purity ATH and HPA products continue to be fully utilised for customer and end-user qualification orders with demand levels now well above existing ATH and HPA production capacity.

Stage One Expansion Options

During the period the Company advanced a number of process optimisation and equipment installation options to increase Stage One production capacity in response to oversubscribed product demand in CY2026 and CY2027.

The Company is assessing further expansion options for Stage One to increase production rates to meet customer demand and to facilitate ongoing growth in customer qualification and testing.

In-house alumina slurry capability for the CMP sector

During the period, the Company was pleased to advance the installation of specialist milling equipment to allow for the Company to have full in-house capability to deliver our novel, ultra-high purity alumina particle as a nano-powder within a liquid dispersion, consistent with the preferred delivery method for our end-users within the CMP sector. To date, the Company has toll milled this product in the US, achieving outstanding performance results as detailed in the Product Marketing section below.

Installation is expected to complete in April 2026, with delivery to CMP end users expected to commence by the end of the 2026 financial year.

Product Marketing

Alpha maintains a continuous global product marketing effort to secure the highest value end-user commitments to support each of its projects. The Company maintains a global network of marketing agents and in-house sales, marketing and technical teams. Product marketing is supported by test sample delivery and commercial sales from the Product Development Centre, located in Brisbane as well as the Stage One facility in Gladstone.

During the period, Alpha's marketing efforts were focused on new demand for new technology trends which match the Company's novel process capability including:

- HPA and high purity ATH for the manufacture of spherical thermal interface materials (fillers) for parallel processing logic semiconductors (Data Centres & Artificial Intelligence **(AI)**);
- HPA for CMP polishing of Silicon-Carbide **(SiC)** semiconductor substrates and hard-carbon masks for High Bandwidth Memory **(HBM)** chips;
- HPA for fine ceramics, with a focus on semiconductor fabrication equipment components;
- High purity, amorphous ATH for DLE sorbents;
- Ultra-high purity Al-Nitrates for battery coatings and solid state electrolytes;
- HPA and high purity Al-hydroxides for a range of pharmaceutical applications; and
- High purity, synthetic sapphire wafers for power-semiconductor and LED substrates.

For personal use only

Directors' Report

Product Marketing (continued)

Summary marketing highlights are listed below, and expanded further in the following sections:

Semiconductor Sector

- Conversion of existing LOI into binding CY2026 supply contract to South Korea for thermal fillers in HBM chip packaging;
- Binding CY2026 supply contracts to Japan under negotiation, for thermal fillers in AI logic chips, with strong price confirmation expected in the coming weeks;
- Monthly record for semiconductor sector shipments in December 2025;
- Fourth round qualification stage underway for sapphire wafers with leading power-semi manufacturer;
- Confirmation of accelerating demand profile and strong product pricing environment for 'zero-alpha emission' aluminas from SEMICON Japan and SEMICON West (US);
- During the period, end-user testing confirms excellent sintering performance for Alpha's high-purity low-alpha alumina for alumina ceramic tooling for semiconductor fabrication equipment; and
- Further outstanding CMP test results from end-users qualifying Alpha's nano-alumina slurry product offering.

Pharmaceutical Sector

- First, high unit value commercial sales and LOI to the pharmaceutical sector established to a high value South Korean end-user, using Alpha's ultra-high purity, high surface area gamma alumina product; and
- MOU (Memoranda of Understanding) established for up to 20tpa to supply high purity materials to the Japanese pharmaceutical and bio-ceramics sector.

All Sectors

- New generation, Al-Nitrate based lithium battery anode coating developed by Tier one anode manufacturer. The Company's coated anode is now with Li-B OEM for final qualification; and
- Additional orders for Alpha's novel, amorphous Al-hydroxide for next generation DLE sorbent development.

Recent marketing activity includes:

- Multiple end-user visits to Japan during the period, including multiple new connections at SEMICON Japan in December 2025.
- Continued strong build up in sales and qualification test orders, now at >500 since May 2024; and
- Alpha successfully hosted two high value end-use site audits to the HPA First Project Stage One and Stage Two facilities during the period.

Product Marketing – Semiconductor Sector

Over the course of CY2025 Alpha has been supporting a dramatic lift in product demand from the semiconductor sector, which has seen the Company supporting multiple end-user product qualifications, low-volume commercial sales from Stage One and negotiating a range of LOIs, MOUs, and related sales contracts.

Alpha is progressively qualifying and supplying its materials for three dominant applications within the sector:

- **Thermal Fillers:** Supply of bespoke milled alpha and gamma phase HPA, as well as fine milled ATH for thermal fillers and thermal interface materials for advanced node semiconductor packaging and encapsulation;
- **CMP:** Supply of Alpha's novel alpha-phase HPA, in both powder and in nano-slurry form, for the use in CMP polishing slurries; and
- **Fine Ceramics:** The more recent supply of high sintering, low-alpha-emission' alumina for the manufacturer of fine alumina-ceramic components in manufacturing equipment for advanced node semiconductors.


For personal use only

Directors' Report

Thermal Fillers

Semiconductor sector demand for Alpha's high purity products in thermal fillers continues to be driven by the interplay of several technology drivers, including:

- **Continued acceleration of capital expenditure allocation to AI infrastructure**, dominated by AI data centres, as well as AI for smart networks and autonomous systems and vehicles. AI infrastructure deployment includes very large scale up of advanced node semiconductors, in both memory and logic processors.
- **Need for improved thermal dissipation and structural strength in advanced node memory and logic semiconductors** driving adoption of high purity alumina as thermal fillers in advanced packaging and encapsulation.
- **Requirement for higher computing output per kilowatt of energy at the data centre level**, to support AI capital infrastructure roll out, increasing adoption of HPA as a thermal filler.
- **Requirement for 'zero alpha emission' materials for advanced node packaging and encapsulation**, being materials which are devoid of any detectable emissions of alpha-particle radiation.
 - At the manufacturing level, this represents as <1 ppb levels for 'alpha emitting' impurities uranium and thorium, a key capability of Alpha's production process and one that sets Alpha apart from competitors globally.
- **End users continue to confirm, that Alpha's high purity alumina materials represent the lowest levels of alpha-emission available** – Please see recent industry feedback below illustrated in the image below.



Consistent with the above, recent marketing highlights within the semiconductor sector includes:

- **Conversion of LOI to binding CY2026 supply contract to South Korea for thermal fillers in HBM chip packaging:** This contract forms the first under an existing LOI for up to 1,000tpa and consolidates the supply into the expanding use of high purity alumina fillers for the encapsulation of advanced node, high bandwidth memory (HBM).
- **Further CY2026 supply contracts for thermal filler under negotiation:** Alpha is negotiating additional supply contracts to Japanese end-users for thermal filler supply to support AI GPU packaging. Customer demand levels are in excess of existing Stage One production capacity in CY2026. Per previous updates, Alpha is reviewing a number of initiatives to manage capacity allocation and increase Stage One capacity in response to existing and expected demand during CY2026 and CY2027.
- **Record semiconductor sector shipments:** Alpha recorded record monthly shipments of 2,240kg to the semiconductor sector in December 2025, dominated by sales of products for thermal fillers to end-users in South Korea and Japan. Each of the shipments were manufactured within the Stage One facility, at unit pricing above those assumed in May 2024 DFS.

For personal use only

Directors' Report

Product Marketing – Semiconductor Sector (continued)

Thermal Fillers (continued)

- **SEMICON Japan:** During the SEMICON Japan conference in December 2025, Alpha was able to secure a range of new end-user connections and initiate new qualification test schedules. In particular, Alpha was able to complete a number of interviews with downstream end-users of high purity alumina fillers, (*“our customer’s customer”*) particularly the suppliers of epoxy encapsulation and advanced packaging materials. Each end user was able to confirm:
 - The use of high purity alumina fillers, as a replacement to silica fillers, is expected to expand rapidly, subject to suitable supply, overwhelmingly driven by the high thermal demands of AI logic and HBM chips used with AI graphics processing units (GPU’s);
 - Adoption of low-alpha alumina fillers is supply constrained, with end-users unable to secure enough materials to meet current or future demand;
 - The requirement for low-alpha alumina is critical, and the availability of a new supplier of ‘zero alpha’ emission aluminas was of high-interest to all sector supplier interviews;
 - The pricing environment for high purity, low-alpha alumina remains very strong; and
 - The internal demand model which estimates >8,000 metric tpa demand by 2030, looks to have materially underestimated demand after allowing for production losses during chip encapsulation, which are estimated by industry end-users at approximately 40 percent.



A portion of semiconductor thermal filler product shipments to end-users, contributing to record monthly shipments in December 2025.

For personal use only

Directors' Report

Product Marketing – Semiconductor Sector (continued)

CMP

The Company has now collected a further set of encouraging end user test results completed on the most recent generations of its nano alumina slurry product (nano dispersion), which represents an approximate 2x downstream value-add to Alpha's novel, alpha phase alumina particle.

Consistent with previous updates, Alpha's novel HPA particles continue to deliver outstanding CMP performance, in terms of both removal rate and selectivity, across a number of emerging semiconductor substrates, including:

- **Silicon Carbide (SiC)** wafers for power semiconductors (driven by electronic vehicles, 5G and solar/wind farm installations);
- **Hard carbon masks**, as increasingly adopted in HBM chips;
- A range of conductive metal substrates; and
- New dielectric layers.

This product development is now close to complete, with high volume manufacturing (**HVM**) of the alumina dispersion due to commence at our Stage One facility in the second half of the 2026 financial year.

Nano alumina dispersion are the dominant input materials for CMP slurries using alumina abrasive.


Final development stage nano-slurries are now being tested across 12 separate CMP OEM's dominated by Japan and US based end-users.

Fine Ceramics

Alpha has collected further-end user test results from the Company's recently developed, high sintering, low-alpha HPA powder (Ultra AAP-X), in the manufacture of alpha-emission sensitive ceramic components for advanced node semiconductor manufacturing.

Results are very encouraging, with Alpha now servicing second round test results in anticipation of servicing first sales orders during the 2026 financial year. Target semiconductor components include vacuum and electrostatic chucks, lifting arms and hold down rings.

The Ultra AAP-X HPA material can deliver maximum theoretical sintered density ($+3.9\text{g/cm}^3$) combined with Alpha's capability of zero-alpha particle emission. Please see example in illustration below:



Directors' Report

Product Marketing – Pharmaceutical Sector



Following a 12+ month customer qualification, Alpha has now commenced ongoing, small-volume, high-value sales to a South Korea based end-user in the pharmaceutical sector and established an LOI for ongoing sales up to 1,000kg pa. The end-use is protein collection, and pricing is approximately double the unit values modelled in the Company's DFS (May 2024).

In December 2025, Alpha established an MOU with a Japanese distributor for the marketing and sale up to 20tpa, with a specific focus on pharmaceuticals and alumina bio ceramics.

Alpha's technology advantage

Over the past five years, Alpha's sales, marketing and technical teams have consolidated the four discrete applications where Alpha's process technology holds a clear advantage over competing manufacturing technologies and/or competing suppliers. This is summarised in the graphic below:

For personal use only

SECTOR	SEMICONDUCTOR			DLE	LITHIUM-ION BATTERY
USE	 THERMAL FILLERS	 CMP	 SEMI - TOOLING	 DLE SORBENTS	 COATINGS
PRODUCTS	Alumina and ATH materials as spherical 'heat sinks' to manage temperature in high performance parallel processors	Alumina abrasives for polishing silicon carbide substrates (Si-C) and package polishing 5N Al-Nitrate additive	High sintering, 'low alpha' HPA for alumina ceramic tool components in advanced node semiconductor	ATH (Al(OH) ₃) as a precursor to make DLE sorbents for extracting lithium from brines	High purity Al-Nitrate as coating precursor to apply Al-based coating on anode materials
A4N ADVANTAGE	Alpha is the only global supplier capable of providing <1ppb U and Th materials for 'low-alpha' thermal interface fillers	Novel process delivers ultra low alkali metals impurities (Na & K) and morphology driving out-performance as a CMP abrasive (up to 50% higher vs industry)	Alpha is the only global supplier of 'low-alpha' alumina with high sintering (+3.9g/cm ³) performance	Novel process delivers unique amorphous ATH crystal structure = ultra-high performance	Alpha is the first company globally to manufacture 5N purity aluminium nitrate MAJOR SAFETY BENEFIT
MARKET DISCOVERY	1,100tpa under LOI (2 OEM's) 1 st Binding contracts in place, 2 nd under draft. 2 x LOIs in draft Qualifying with 6 x other Premium pricing ~ US\$25-35/kg Est. unmet demand: +8ktpa	4,000tpa under LOI Small scale sales commenced Qualifying for 10 x other Strong pricing ~US\$20-30/kg Est. unmet demand:+2.3ktpa	Alpha is <u>early stage</u> outreach only. Total potential demand est. +5ktpa	LOI in draft Qualifying with 14 x counterparties Moderate pricing Est unmet demand: +15ktpa	Qualified with a sector leader 2 x LOI + quotation in draft Moderate pricing (strong in HPA Eq) Est unmet demand: +10ktpa

Directors' Report

HPA First Project - Stage Two

The Company continues to make significant progress across critical workstreams for construction and delivery of Stage Two including, civil works, procurement, engineering and fabrication, construction and operational team readiness as outlined below.

Safety, Health and Environment

The Company prioritises the safety and wellbeing of our people and is focused on ensuring that safety is at the forefront of decision making. Alpha is pleased to note that the Recordable Work Injury (RWI) frequency rate on the project was zero for the reporting period.

Site delivery of first large scale, offsite fabricated process equipment

The first large scale, offsite fabricated equipment was delivered to the project site in December 2025 via a dedicated sea freight service. Site assembly will commence in quarter 3 of the 2026 financial year under the first SMP contract, which was awarded during the period.



Dedicated sea freight, offload at Gladstone port & first delivery to site of major process equipment

Major Civil Works

Concrete civil works continued across multiple areas, with several construction areas successfully completed and handed over for installation by SMP contractors, including the by-product tank farm, evaporators, Orica reagent storage areas. Concrete works for initial Orica reagents and SX were completed during the period, with concrete poured to date totaling approximately 2,800m³. The Alpha team continue to focus on finishing off the SX areas and are moving towards pipe rack foundations for both the east-west and north-south pipe rack spines.

For personal use only

Directors' Report

HPA First Project - Stage Two (continued)



Orica Reagent Tanks staged for installation



Four dilute aluminium nitrate tanks on foundations

For personal use only

Directors' Report

HPA First Project - Stage Two (continued)



SX area civils nearing completion

Engineering and Fabrication

Detailed engineering continues to feed the project's critical path, with structural steel, piping and parallel Electrical and Instrumentation (E&I) design progressing to support the release of fabrication and construction work fronts. Offsite fabrication remains on schedule, highlighted by the successful delivery of the first tranche of site erected tanks to site and major SX circuit components to Gladstone, together with strong manufacturing progress on long lead equipment such as the Rotary Dryer and Calciner.

Fabrication of structural steel and piping has commenced, including the first major pipe rack modules. Procurement progressed well through the period, with multiple packages released into manufacture, key equipment successfully passing Factory Acceptance Testing to maintain delivery sequencing. The project remains well positioned, with all major procurement packages awarded and multiple key equipment deliveries now successfully arriving in Gladstone and on site.

Construction

The first SMP installation contractor mobilised to site, including assembly of a 250t crawler crane for installation of major tanks and SX equipment from January 2026. This mobilisation marks the transition into high volume mechanical installation in the second half of the 2026 financial year.

Preparation of the next SMP and E&I installation packages is progressing to maintain construction momentum. Earthworks on the southern plot have progressed well, creating additional temporary construction space to ease site congestion during upcoming peak activity periods.

Operations Readiness

The operations readiness team has been expanded with key appointments in Production, Maintenance and Health, Safety and Environment. Implementation of the maintenance management system has progressed with user acceptance testing being completed during the period and plans to go live for Stage One in the second half of the 2026 financial year. Key appointments have also been made for the Commissioning Manager and Completions Engineer roles. Implementation of the completions and handover system is on track for the commencement of structural, mechanical and piping construction.

For personal use only

Directors' Report

HPA First Project - Stage Two (continued)



Stage Two Project site – looking west to Orica (mid ground) and Rio Tinto Yarwun (far ground) February 2026

Alpha Sapphire

Alpha Sapphire is a wholly owned subsidiary of Alpha that has invested in an initial two, next-generation sapphire glass growth units (Phase A) as qualification units prior to decision on the commercial scale deployment of synthetic sapphire growth (Phase B and Phase C).

The Phase A units are currently running multiple sapphire growth runs within Stage One of the HPA First Project using the Company's in-house high-purity alumina feedstock to provide synthetic sapphire for sales and end-user qualification.

Marketing Update

During the period Alpha Sapphire entered the fourth round of 200mm sapphire wafer qualification with a European tier one manufacturer of power semiconductors that is developing next generation Gallium-Nitride (GaN)-on-sapphire semiconductor platforms.

GaN-on-sapphire is an emerging semiconductor technology for high power and high-frequency devices. GaN-on-sapphire semiconductors are grown on wider format (8") C-plane sapphire wafers and are considered an excellent match to the capabilities of Alpha Sapphire's sapphire growth units which are optimised for wide-format C-axis sapphire growth.

The fourth round request for additional wafers follows three successful rounds of supply of 200mm sapphire wafers.

For personal use only

Directors' Report

Corporate

QCMBTF: Queensland Government

In October 2025 the Company announced it had executed a binding transaction documentation with the Trustee of the QIC Critical Minerals and Battery Technology Fund (QCMBTF) to change the terms of the existing \$30 million commitment provided to the Company's 100percent owned subsidiary, Alpha Sapphire. The QCMBTF has entered into new Royalty Deeds with wholly owned subsidiaries of Alpha to provide a source of funding across the entire Alpha HPA business. Conditions Precedent to Financial Close have been satisfied and the facility has been drawn in full resulting in \$27 million of funding being received for Stage Two and general corporate purposes, with \$3 million used to repay the drawn portion of the existing Sales Support Production Facility, to support customer qualification.

NAIF/EFA: Australian Government

Since reaching Contractual Close on \$400 million in senior debt financing with Export Finance Australia (EFA) and the Northern Australia Infrastructure Facility (NAIF), the Company has continued to work closely with both lenders to meet all remaining conditions precedent to Financial Close as soon as possible. The Company also worked with the lenders to ensure terms of the QIC royalty investment were acceptable.

Appointment of Mr Peter Ware as COO

In September 2025, Alpha was delighted to welcome Mr Peter Ware as Chief Operations Officer (COO). With a background in chemical engineering and more than 20 years of senior leadership experience across mining, chemicals and manufacturing, Mr Ware has led operational turnarounds, major capital projects and emissions reduction programs across Australia and South Africa. Most recently, he was Vice President – Australian Manufacturing at Incitec Pivot Limited, responsible for all operations across the country.

Subsequent Events

In January 2026 the Company announced a \$225 million, two tranche equity raising to new and existing institutional investors, as well as a Share Purchase Plan (SPP). The Company completed the issuance of the 140,000,000 Tranche 1 placement shares in February 2026, raising \$105 million before costs. The Tranche 2 placement shares will be issued upon shareholder approval at an Extraordinary General Meeting to be held on 11 March 2026.

Conditions subsequent to \$30 million drawdown from QCMBTF were satisfied on 30 January 2026.

Other than the matters outlined above, no matters or circumstances have arisen since the end of the reporting period, which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

Auditor's Independence Declaration

A copy of the Auditor's Independence Declaration on page 16 as required under Section 307C of the Corporations Act 2001 is attached to, and forms part of the Directors' Report for the half-year ended 31 December 2025.

Signed in accordance with a resolution of the Directors.



Norman A. Seckold
Chairman
Sydney, 26 February 2026

For personal use only



Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the Directors of Alpha HPA Limited

I declare that, to the best of my knowledge and belief, in relation to the review of Alpha HPA Limited for the half-year ended 31 December 2025 there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- ii. no contraventions of any applicable code of professional conduct in relation to the review.

KPMG

KPMG

Adam Twemlow
Partner

Brisbane
26 February 2026

For personal use only

Condensed Consolidated Interim Statement of Profit and Loss and Other Comprehensive Income

For the half-year ended 31 December 2025

	Notes	31 December 2025 \$	31 December 2024 ¹ \$
Revenue and other income			
Sales revenue		263,616	71,067
Expenses			
Changes in inventories of finished goods and work in progress		(1,089,336)	(2,160,473)
Raw materials and consumables		(408,074)	(823,459)
Employee expenses	3a	(7,991,880)	(5,783,933)
Purchased services	3b	(5,124,518)	(5,881,471)
Depreciation and amortisation		(2,218,966)	(1,549,566)
Repairs and maintenance		(998,422)	(1,261,309)
Share based payments	9	(3,039,170)	(1,759,613)
Other expenses	3c	(3,937,710)	(2,342,365)
Unrealised gain on investments	6	657,444	1,586,320
Loss before net finance income		(23,887,016)	(19,904,802)
Finance income		1,550,308	4,529,890
Finance expense		(201,416)	(465,039)
Net finance income		1,348,892	4,064,851
Loss before income tax		(22,538,124)	(15,839,951)
Income tax expense		-	-
Loss for the period		(22,538,124)	(15,839,951)
Other comprehensive income for the period			
Items that may be reclassified subsequently to profit or loss:			
Foreign currency translation		-	-
Total other comprehensive income/(loss)		-	-
Total comprehensive loss for the period		(22,538,124)	(15,839,951)
Earnings per share attributable to the ordinary equity holders			
Basic and diluted loss per share		(1.98)	(1.40)

The above statement should be read in conjunction with the accompanying notes.

¹ Comparative results have been reclassified by nature. The reclassifications did not result in any net change to Profit or Loss after Tax for the comparative period.

Condensed Consolidated Interim Statement of Financial Position

As at 31 December 2025

	Notes	31 December 2025 \$	30 June 2025 \$
Current assets			
Cash and cash equivalents		45,070,906	102,035,989
Term deposits		867,843	-
Trade and other receivables	4	9,267,413	14,011,131
Prepayments		23,699,317	13,914,188
Inventory		4,559,864	4,335,581
Total current assets		83,465,343	134,296,889
Non-current assets			
Trade and other receivables	4	8,437,500	11,250,000
Property, plant and equipment	5	198,676,001	124,706,231
Intangible assets		3,399,208	3,531,842
Right-of-use-assets		2,727,448	782,204
Investments	6	4,206,497	3,549,053
Term deposits		4,437,845	5,255,189
Total non-current assets		221,884,499	149,074,519
Total assets		305,349,842	283,371,408
Current liabilities			
Trade and other payables	7	39,536,972	20,379,397
Deferred consideration		85,703	134,759
Deferred grant recognition	10	7,631,250	25,968,087
Lease liabilities		1,421,364	549,956
Other financial liabilities		-	3,533,535
Total current liabilities		48,675,289	50,565,734
Non-current liabilities			
Deferred consideration		703,738	701,313
Lease liabilities		1,696,834	331,878
Deferred grant recognition	10	23,412,451	11,250,000
Provisions		1,330,466	1,646,772
Other financial liabilities	11	23,722,701	-
Total non-current liabilities		50,866,190	13,929,963
Total liabilities		99,541,479	64,495,697
Net assets		205,808,363	218,875,711
Equity			
Issued capital	8	357,022,965	352,718,198
Reserves	8	9,198,183	4,032,174
Accumulated losses		(160,412,785)	(137,874,661)
Total equity		205,808,363	218,875,711

The above statement should be read in conjunction with the accompanying notes.

Condensed Consolidated Interim Statement of Changes in Equity

For the half-year ended 31 December 2025

	Notes	Issued Capital	Reserves	Accumulated Losses	Total
		\$	\$	\$	\$
Opening equity as at 1 July 2024		348,983,987	3,350,740	(105,159,743)	247,174,984
Loss for the period		-	-	(15,839,951)	(15,839,951)
Total comprehensive loss		-	-	(15,839,951)	(15,839,951)
Transactions with owners in their capacity as owners					
Issue of shares	8	1,543,700	-	-	1,543,700
Cost of share issue	8	(12,528)	-	-	(12,528)
Share-based payments		-	215,914	-	215,914
Total contributions by and distributions to owners		1,531,172	215,914	-	1,747,086
Closing equity as at 31 December 2024		350,515,159	3,566,654	(120,999,694)	233,082,119
Opening equity as at 1 July 2025		352,718,198	4,032,174	(137,874,661)	218,875,711
Loss for the period		-	-	(22,538,124)	(22,538,124)
Total comprehensive loss		-	-	(22,538,124)	(22,538,124)
Transactions with owners, in their capacity as owners					
Issue of shares	8	3,534,161	(3,484,161)	-	50,000
Cost of share issue	8	(18,394)	-	-	(18,394)
Fair Value of Options exercised during the period	8	789,000	(789,000)	-	-
Share based payments		-	3,039,170	-	3,039,170
Grant of options	8	-	6,400,000	-	6,400,000
Total contributions by and distributions to owners		4,304,767	5,166,009	-	9,470,776
Closing equity as at 31 December 2025		357,022,965	9,198,183	(160,412,785)	205,808,363

The above statement should be read in conjunction with the accompanying notes.

For personal use only

Condensed Consolidated Statement of Cash Flows

For the half-year ended 31 December 2025

	Notes	31 December 2025 \$	31 December 2024 \$
Cash flows from operating activities			
Receipts from customers		241,119	71,067
Cash payments in the course of operations		(25,252,993)	(35,446,827)
Payments for research and development expenditure		(1,424,859)	(1,332,809)
Research and development incentive		3,107,148	6,182,415
Interest received		1,406,722	3,052,428
Net cash outflow from operating activities		(21,922,863)	(27,473,726)
Cash flows from investing activities			
Payments for plant and equipment		(64,039,516)	(21,808,451)
Receipts (payments) for security deposits		(50,499)	(4,213,529)
Term deposit placements		-	(50,000,000)
Government grants		2,550,000	12,150,000
Net cash outflow from investing activities		(61,540,015)	(63,871,980)
Cash flows from financing activities			
Proceeds from the issue of shares	8	50,000	-
Share issue transactions costs	8	(3,283)	(4,727)
Receipts from borrowing activities		27,000,000	-
Repayment of lease liabilities		(397,317)	(98,140)
Net cash inflow/(outflow) from financing activities		26,649,400	(102,867)
Decrease in cash and cash equivalents			
Cash and cash equivalents at 1 July		102,035,989	189,618,503
Effects of exchange rate changes on cash and cash equivalents		(151,605)	718,479
Cash and cash equivalents at end of the period		45,070,906	98,888,409

The above statement should be read in conjunction with the accompanying notes.

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

1. Reporting Entity

Alpha HPA Limited ('the Company') is a company limited by shares incorporated and domiciled in Australia, whose shares are publicly traded on the Australian Securities Exchange. The Interim Financial Report for the half-year ended 31 December 2025 comprises the Company and its controlled entities (together referred to as 'the Group').

The Group is a for-profit entity and the principal activities are the development and production of high purity aluminum products for the battery, LED and semi-conductor markets, as well as synthetic sapphire glass.

2. Basis of Preparation

(a) Statement of compliance

The Condensed Consolidated Interim Financial Statements have been prepared in accordance with the Corporations Act 2001 (Cth) and Australian Accounting Standard AASB 134 'Interim Financial Reporting'.

The Condensed Consolidated Interim Financial Statements do not include full disclosures of the type normally included in the Annual Financial Report. Accordingly, this report is to be read in conjunction with the Annual Financial Report for the year ended 30 June 2025 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 (Cth) and the ASX Listing Rules.

The Condensed Consolidated Interim Financial Statements were authorised for issue by the Directors on 26 February 2026.

(b) Estimates

The preparation of the Interim Financial Report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by Management in applying the Group's accounting policies and the key sources of estimation uncertainty were consistent with those in the Annual Financial Report for the year ended 30 June 2025. These were:

- Accounting for research and development activities, which involves distinguishing between research and development activities in accordance with AASB 138. Management have determined that the criteria to capitalise development costs for the full scale HPA First plant has not been met during the period.
- Share based payments;
- Unrecognised deferred tax assets;
- Intellectual property licensing rights;
- Recognition of government grants received; and
- Accounting for QIC borrowings.

(c) Changes in accounting policies

A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after 1 January 2026 and have not been applied in preparing this Interim Financial Report. None of these are expected to have a significant effect on the interim financial statements of the Group.

(d) Going concern

The Condensed Consolidated Interim Financial Statements have been prepared on a going concern basis, which contemplates the continuation of normal business operations and the realisation of assets and settlement of liabilities in the normal course of business. The Group incurred a loss after tax of \$22,538,124 (2024 - \$15,839,951) and had net cash outflows from operating and investing activities, \$83,462,878 (2024 - \$91,345,706) for the half year ended 31 December 2025. At period end the Group had available cash and cash equivalents of \$45,070,906.

The Group's main activity is development of the HPA First Project and as such it does not presently have a material source of operating income, rather it is reliant on funds from equity raising or from other external sources to fund its activities.

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

(d) Going concern (continued)

Subsequent to 31 December 2025 the Group successfully completed a fully underwritten equity raising of \$225 million via a two-tranche placement of new fully paid ordinary shares of which \$120 million is conditional upon shareholder approval at an Executive General Meeting scheduled on 11 March 2026.

Management have prepared cash flow projections for the period from 1 January 2026 to 28 February 2027 that support the ability of the Group to continue as a going concern. These cash flow projections assume significant net cash outflows from operating and investing activities, particularly with the ongoing construction of Stage 2 of the HPA First Project. Management have prepared cashflow forecasts which indicate that under alternate scenarios the Group can meet its current contractual capital commitments and its forecast operating cash outflows based on available funding. On this basis, the Directors consider the going concern basis of preparation of the Condensed Consolidated Interim Financial Statements is appropriate.

(e) Reclassification of prior period expenses

For the half year-ended 31 December 2025, the Group elected to change the presentation of certain amounts in the Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income. This change reflects the Group's decision to classify expenses by their nature which Management considers to provide more relevant and meaningful information to readers of the Interim Financial Report. Comparative results have been reclassified accordingly to align with the updated presentation. These reclassifications did not result in any net change to Profit or Loss after Tax for the comparative period.

3. Breakdown of expenses

	31 December 2025 \$	31 December 2024 \$
a) Employee Expenses		
Salary and wages	6,322,170	4,814,706
Superannuation	748,165	524,680
Other employee benefits	921,545	444,547
Total employee expenses	7,991,880	5,783,933
b) Purchased Services		
Audit, legal and insurance	892,416	878,064
Contractors and consultants	2,236,012	2,876,010
Marketing services	683,226	873,289
Other services	1,312,864	1,254,108
Total Purchased services	5,124,518	5,881,471
c) Other Expenses		
Corporate and other administration expenses	3,393,352	2,126,611
Land taxes and rates	299,395	208,897
Other	244,963	6,857
Total other expenses	3,937,710	2,342,365

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

4. Trade and other receivables

	31 December 2025 \$	30 June 2025 \$
Government grant receivable	8,479,167	8,500,000
GST receivable	485,065	1,481,160
R&D rebate receivable	-	3,107,148
Interest receivable	129,801	271,940
Other receivables	173,380	650,883
Current trade and other receivables	9,267,413	14,011,131
Government grant receivable	8,437,500	11,250,000
Non-current trade and other receivables	8,437,500	11,250,000

5. Property, plant and equipment

	31 December 2025 \$	30 June 2025 \$
Construction in progress*	168,542,576	79,791,442
Plant, machinery and equipment*	15,345,723	29,900,936
Building	12,007,807	12,365,002
Land	2,648,851	2,648,851
Leasehold improvements	131,044	-
Property, plant and equipment	198,676,001	124,706,231

*\$29,653,294 of government grant income has been recognised in property, plant and equipment, offsetting against the carrying value of construction in progress, since commencement of construction. (June 2025: \$23,478,908).

6. Investments

	31 December 2025 \$	30 June 2025 \$
Investments – Opening balance	3,549,053	2,240,472
Additions	-	98,618
Unrealised gain	657,444	1,209,963
Investments – Closing balance	4,206,497	3,549,053

As at 31 December 2025 the Company held the following shares in ASX listed entities:

- 17,125,000 shares in Far East Gold Limited, the fair value of which was \$2,654,375;
- 20,000,000 shares in Helix Resources Limited the fair value of which was \$40,000; and
- 1,643,610 shares in Santana Minerals Limited, the fair value of which was \$1,512,122.

Fair value is based on the closing market value of the shares on the last day of trading on the ASX to 31 December 2025. The fair value measurements for the Group's investments have been categorised as Level 1 fair values based on quoted prices in an active market for identical assets.

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

7. Trade and other payables

	31 December 2025 \$	30 June 2025 \$
Trade creditors	8,193,351	4,255,206
Sundry creditors and accruals	26,093,621	9,124,191
Debt funding upfront fees	5,250,000	7,000,000
Current trade and other payables	39,536,972	20,379,397

Under the terms of the Syndicated Facility Agreement (SFA) with Export Finance Australia (EFA) and the Northern Australia Infrastructure Facility (NAIF) the Company is required to pay upfront fees of \$5,250,000 upon first drawdown. Drawdown of the SFA remains subject to satisfaction of conditions that are typical for a facility of this nature (including Solindo securing letters of intent and product qualification for a minimum aggregate volume of production).

8. Capital and Reserves

	Number of shares	31 December 2025 \$	Number of shares	30 June 2025 \$
Issued and paid-up capital	1,141,282,930	357,022,965	1,137,002,297	352,718,198
	Number of shares	31 December 2025 \$	Number of shares	30 June 2025 \$
Ordinary Shares				
Opening balance	1,137,002,297	352,718,198	1,134,580,693	348,983,987
Issue of shares	52,966	50,000	521,030	468,927
Exercise of options	216,495	789,000	105,574	1,738,800
Vesting of performance rights	4,011,172	3,484,161	1,795,000	1,543,700
Costs of issue	-	(18,394)	-	(17,216)
Closing balance	1,141,282,930	357,022,965	1,137,002,297	352,718,198

During the period, the Company issued 4,011,172 ordinary shares following the vesting of 4,011,172 performance rights.

Shares valued at grant date of \$789,000 were issued by the Company following the cashless conversion of 3,000,000 options during the period. The exercise price was \$0.90 per option. During the period, the Company also placed 52,966 shares at \$0.944 per share to Port Curtis Coral Coast Limited (PCCC), raising \$50,000. PCCC acts as Trustee for the Port Curtis Coral Coast Aboriginal Peoples Charitable Trust (PCCC Trust). As part of the placement, the PCCC Trust have also been issued 500,000 options at a strike price of \$1.13 with a 3-year expiry from the date of the placement.

Nature and purpose of reserves

Option premium and performance rights reserve

The option premium and performance rights reserves are used to recognise the grant date fair value of options and rights vested but not exercised.

Foreign currency translation reserve

The foreign currency translation reserve records the foreign currency differences arising from the translation of the financial statements of foreign operations where their functional currency is different to the presentation currency of the reporting entity.

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

8. Capital and Reserves (continued)

	31 December 2025 \$	30 June 2025 \$
Option premium reserve	6,530,000	789,000
Performance rights reserve	2,648,904	3,223,895
Foreign current translation reserve	19,279	19,279
Closing balance	9,198,183	4,032,174
Movements during the period		
Option premium reserve		
Opening balance	789,000	2,342,998
Share options issued – share based payments	130,000	25,202
Exercise of options	(789,000)	(1,738,000)
Transfer to option premium reserve	-	159,600
Grant of options to QIC	6,400,000	-
Closing balance	6,530,000	789,000
Foreign currency translation reserve		
Opening balance	19,279	19,279
Closing balance	19,279	19,279
Performance rights reserve		
Opening balance	3,223,895	988,463
Issue of performance rights	2,909,170	3,897,359
Vesting of performance rights	(3,484,161)	(1,543,700)
Cancellation of performance rights	-	(118,227)
Closing balance	2,648,904	3,223,895

As consideration for the QCMBTF corporate funding (see Note 11), the Company issued 20,000,000 \$1.00 options for no consideration with a grant date of 31 October 2025 and an expiry date of 31 October 2029, to QBF No.1 Pty Ltd.

The fair value of the options granted has been measured using the Black-Scholes method, taking into account the terms and conditions upon which the options were granted. The fair value of the options granted was \$0.32 per share, totalling \$6,400,000 and was capitalised into Other financial liabilities, to be amortised using an effective interest rate, over the term of the royalty agreement. An amortisation expense of \$63,514 was recognised during the period.

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

9. Share Based Payments

Options

As at 31 December 2025, unissued ordinary shares of the Company under option were:

Number of options	Exercise price	Expiry date	Expense recognised during current period
500,000	\$1.13	1 August 2028	\$130,000
20,000,000	\$1.00	31 October 2029	-

During the period, the Company issued 500,000 options for no consideration, with a strike price of \$1.13 per option to the PCCC. The options had a grant date of 1 August 2025 and an expiry date of 1 August 2028. The fair value of the options granted has been measured the Black-Scholes model, taking into account the terms and conditions upon which the options were granted. The fair value of the options granted was \$0.26 per share, totalling \$130,000. The options vested immediately on granting and a share based payment expense of \$130,000 was recognised during the period.

Performance Rights

Following approval at the 2025 Annual General Meeting, the Company issued 1,292,213 performance rights with market-based conditions to Executive Directors Norman Seckold, Rimas Kairaitis, Robert Williamson and Chief Financial Officer (CFO), Craig Jones. The rights were valued using a Monte-Carlo simulation. Their vesting depends on the Company's absolute Total Shareholder Return (TSR) growth over the performance period.

TSR Performance of the Company:	Vesting Outcome:
- below 10% per annum cumulative TSR growth over the performance period	0% of the share rights will vest
- between 10% and 20% per annum cumulative TSR growth over the performance period	vesting will be on a sliding scale between 0% and 100% of the share rights
- more than 20% per annum cumulative TSR growth over the performance period	100% of the share rights will vest

The TSR growth over the performance period will be based on the Ending TSR, divided by Starting TSR, where:

- the Starting TSR will be the volume weighted average price (VWAP) of the Company's shares traded on the ASX for the twenty trading days up to 30 June 2025.
- the Ending TSR will be calculated using the volume weighted average price (VWAP) of the Company's shares traded on the ASX for the twenty trading days up to 30 June 2028, with consideration of reinvested dividends.

The fair value of the rights granted was \$0.4257 per right, totalling \$550,095. A share-based payment expense of \$19,080 was recognised during the reporting period.

Following the Company's 2025 Company's Annual General Meeting, at which shareholder approval was sought to issue performance rights to Executive Directors, the Company issued 742,344 performance rights to Norman Seckold, Rimas Kairaitis and Robert Williamson and CFO Craig Jones, based on the FYI Short Term Incentive (STI) outcomes. The Board of Directors assessed KMP performance and determined that Mr Seckold, Mr Kairaitis and Mr Williamson earned an STI outcome for FY25 that was 64% of the maximum award. This outcome is reflective of performance against pre-determined business objectives and individual performance criteria approved by the Board of Directors. Half of the STI is delivered in Rights that vested immediately, and half are deferred to vest after two years, subject to continued employment.

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

9. Share Based Payments (continued)

The number of rights to be granted was determined based on the 20-day VWAP of the Company's shares to 30 June 2025, of \$0.8182. The fair value of the 742,344 rights granted was \$0.7350 per right, totalling \$545,623 and were valued using a Monte-Carlo simulation. This is the closing price of the Company's shares on 26 November 2025 (the date the rights were issued). A share-based payment expense of \$287,661 was recognised during the period.

In December 2025 the Company issued 1,274,309 performance rights with market-based conditions to Senior Managers of the Company. The vesting conditions were the same as those issued to Executive Directors, as detailed above. The fair value of the rights granted was \$0.3983 per right, totalling \$507,557 and were valued using a Monte-Carlo simulation. A share-based payment expense of \$6,177 was recognised during the period.

Additionally, during the period, the Company issued 3,660,000 service based performance rights for no consideration. The fair value of rights was the Company's closing share price of \$0.7150 on 19 December 2025 (grant date). The rights vest in thirds on 14 December 2026, 14 December 2027 and 14 December 2028. The fair value of the service based rights granted was \$2,616,900. A share based payment expense of \$53,109 was recognised during the period.

At 31 December 2025, performance rights of the Company on issue are:

Number of rights	Basis	Vesting	Expense recognised during current period
1,625,000	Service based	1/3 December 2026	\$550,018
180,000	Performance based	Subject to share price performance	\$15,613
718,403	Performance based	Subject to share price performance	\$77,602
4,050,000	Service based	1/3 December 2026 1/3 December 2027	\$1,899,910
1,292,213	Performance based	Subject to share price performance	\$19,080
371,172	Performance based	Subject to performance criteria	\$287,661
3,660,000	Service based	1/3 December 2027 1/3 December 2028 1/3 December 2029	\$53,109
1,274,309	Performance based	Subject to share price performance	\$6,177

10. Deferred Grant Recognition

	31 December 2025 \$	30 June 2025 \$
Opening balance	25,968,087	5,913,029
Increase/(decrease)	(12,162,451)	28,175,000
Grant recognition into CIP/PP&E	(6,174,386)	(8,119,942)
Current - Deferred Grant Recognition	7,631,250	25,968,087
Opening balance	11,250,000	-
Increase	12,162,451	11,250,000
Non-current – Deferred Grant Recognition	23,412,451	11,250,000

During the period, the Company received \$3,116,666 in Federal Government proceeds (GST inclusive) related to the Modern Manufacturing Initiative – MMI-C grant, 10% of which will be been paid to Orica, per the terms of the grant at the date of this report. During the period the entity has also recognised a portion of the grant proceeds as an offset to Property, machinery and equipment. This is calculated as earned based on the proportion of life to date expenditure and total project cost. The grants received and not yet earned are recorded as Deferred Grant recognition.

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

11. Other Financial Liabilities

QIC Critical Minerals and Battery Technology Fund – Royalty

On 21 October 2025, new binding royalty deeds were executed with the Trustee for the QIC Critical Minerals and Battery Technology Fund (QCMETF) to change the terms of the existing \$30 million commitment. The new arrangements provide for royalty payments in exchange for the funding drawn and are summarised below:

- \$27 million in proceeds drawn down on 30 October 2025 for its wholly owned subsidiary, Solindo Pty Ltd, with a royalty payable based on the gross revenue proceeds received for HPA products. These funds will support the development and construction of the Stage Two HPA First Project as well as general corporate purposes. Funding is secured by second ranking security interest granted by Solindo Pty Ltd and Alapex Pty Ltd over all its assets, ranking behind the senior EFA/NAIF facility agreement.
- \$3 million in proceeds (drawn down on 9 November 2023) to Alpha Sapphire Pty Ltd, a wholly owned subsidiary focused on sapphire growth technologies. A royalty is payable based on gross revenue from Alpha Sapphire product sales. Funding is secured by first ranking security interest granted by Alpha Sapphire Pty Ltd and Augur Investments Pty Ltd.

	31 December 2025 \$	30 June 2025 \$
Opening balance	3,533,535	218,760
QCMETF Royalty Liability	(3,533,535)	3,000,000
Interest	-	314,775
Current – Other financial liabilities	-	3,533,535
Opening balance	-	3,000,000
QCMETF Royalty Liability	30,000,000	(3,000,000)
Borrowing Costs	(6,993,896)	-
Interest	716,597	-
Non-current – Other financial liabilities	23,722,701	-

The financial liability has been initially measured at fair value, using amortised cost using an effective interest rate appropriate to the terms of the contract. Judgement has been applied in determining the initial accounting of this liability in accordance with AASB 132 Financial Instruments: Presentation and AASB 9 Financial Instruments. In accordance with the relevant standards, the requirement to deliver cash based on uncertain future events, including future revenues, gives rise to a financial instrument. The royalty deeds do not meet the criteria to be classified as an equity instrument, and as a result have been accounted for as a financial liability.

Accrued interest expense of \$533,535 associated with original QCMETF royalty deed with Alpha Sapphire was extinguished during the period, as Management consider the new royalty deed to be a substantial modification under AASB 9 Financial Instruments. Interest accrued of \$716,597 relating to the new royalty deeds was recognised during the period.

A quarterly royalty payment will be payable using a rate of 1.50%, 1.25%, 1.00% or 0.75% (depending on whether certain production targets are met) multiplied by the gross revenue received by the Company from the HPA First Project and Alpha Sapphire.

The royalties will terminate upon an aggregate amount of 200,000 tonnes of product produced and sold from the HPA First Project. The QCMETF enjoys the benefit of security over all assets of HPA First project and Sapphire subsidiaries. Upon the release of sponsor completion support under the senior EFA/NAIF facility agreement, security over Alpha HPA Limited's shares in Augur Investments Pty Ltd and bank accounts, along with Alpha HPA Limited's guarantee of the Royalty obligations will come into effect. Security over Alpha HPA Limited's shares in Alapex Pty Ltd and related receivables will only attach upon full repayment of the senior EFA/NAIF debt. All security will be released upon QCMETF receiving \$45 million in royalty payments.

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

11. Other Financial Liabilities (continued)

The senior debt under the EFA/NAIF facility ranks ahead of the Royalty under the Alpha HPA Royalty Deed in right of payment and on enforcement. During the priority period (from first drawdown under the EFA/NAIF facility until full repayment), Royalty payments may only be made from amounts available for permitted distributions under the EFA/NAIF facility. Upon full repayment of senior debt, any accumulated unpaid Royalty will become payable, the security under the Alpha HPA Royalty Deed will become first-ranking, and security will extend to Alpha HPA Limited's shares in Alapex Pty Ltd.

12. Segment Reporting

Segment information is presented in respect of the Group's management and internal reporting structure.

Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items comprise mainly income earning assets and revenue, interest bearing loans, borrowings and expenses, and corporate assets and expenses.

Segment capital expenditure is the total cost incurred during the period to acquire segment assets that are expected to be used for more than one period in that geographic region.

For the half-year ended 31 December 2025, the Group had two segments, being development of the HPA First Project and the Alpha Sapphire Project.

	HPA First Project \$	Alpha Sapphire Project \$	Total \$
31 December 2025			
Revenue	216,641	88,790	305,431
Reportable segment loss before tax	16,172,446	597,028	16,769,474
Reportable segment assets	253,460,419	4,771,542	258,231,961
Reportable segment liabilities	93,286,140	2,453,594	95,739,734
31 December 2024			
Revenue	55,788	15,279	71,067
Reportable segment loss before tax	16,425,405	807,288	17,232,693
Reportable segment assets	150,334,238	6,545,656	156,879,894
Reportable segment liabilities	52,289,025	3,628,366	55,917,391

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

12. Segment Reporting (continued)

	31 December 2025 \$	31 December 2024 \$
Reconciliations of reportable segment revenues and profit or loss		
Total loss for reportable segments	(16,769,473)	(17,232,693)
Unallocated amounts:		
Interest income	1,711,207	3,811,116
Net other corporate expenses	(7,479,859)	(2,418,374)
Consolidated loss before tax	(22,538,125)	(15,839,951)
Reconciliations of reportable assets and liabilities		
Assets		
Total assets for reportable segments	258,231,961	156,879,894
Unallocated corporate assets	47,117,781	142,944,162
Consolidated total assets	305,349,742	299,824,056
Liabilities		
Total liabilities for reportable segments	95,739,734	55,917,391
Unallocated corporate liabilities	3,801,745	10,824,546
Consolidated total liabilities	99,541,479	66,741,937

For personal use only

Notes to the Condensed Consolidated Interim Financial Statements

For the half-year ended 31 December 2025

13. Related Parties

Key management personnel and Director transactions

A number of key management persons, or their related parties, hold positions in other entities that result in them having control or joint control over the financial or operating policies of those entities.

These entities transacted with the Group during the half-year as follows:

- During the half-year year ended 31 December 2025, Norman Seckold held a controlling interest in an entity, MIS Corporate Pty Ltd, which provided administration services to the Group, including rental accommodation, administrative, accounting and investor relations staff both, services and supplies. Fees charged by MIS Corporate Pty Ltd during the half-year totalled \$131,550 (31 December 2024 - \$150,000). At 31 December 2025 there was nil outstanding (31 December 2024 - \$nil).
- During the half-year year ended 31 December 2025, Annie Liu held a controlling interest in an entity, Alto Group Inc, which provided advisory services to the Group. Fees charged by Alto Group Inc during the half-year, excluding Director's Fees, totalled \$54,107 (31 December 2024 - \$148,502). At 31 December 2025 there was nil outstanding (31 December 2024 - \$nil).

14. Financial Instruments

Financial risk management

The Group's financial risk management objectives and policies are consistent with those disclosed in the consolidated annual financial report as at and for the year ended 30 June 2025.

Carrying amounts versus fair values

The carrying amounts of financial assets and financial liabilities included in the balance sheet approximate fair values.

15. Subsequent Events

Capital Raise

In January 2026 the Company announced a \$225 million, two tranche equity raising to new and existing institutional investors, as well as a Share Purchase Plan. The Company completed the issuance of the 140,000,000 Tranche 1 placement shares in February 2026, raising \$105 million before costs. The Tranche 2 placement shares will be issued upon shareholder approval at an Extraordinary General Meeting to be held on 11 March 2026.

QCMETF Funding

Conditions subsequent to \$30 million drawdown from QCMETF were satisfied on 30 January 2026.

Other than the matter outlined above, no matters or circumstances have arisen since the end of the reporting period, which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

For personal use only

Directors' Declaration

In accordance with a resolution of the Directors of Alpha HPA Limited, I state that:

In the opinion of the Directors:

- (a) the interim financial report and notes set out on pages 17 to 31 are in accordance with the *Corporations Act 2001* including:
 - (i) giving a true and fair view of the Group's financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
 - (ii) complying with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Regulations 2001; and
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

The Directors have been given the declarations required by Section 295A of the Corporations Act 2001 from the chief executive officer and chief financial officer for the financial half year ended 31 December 2025.

Signed in accordance with a resolution of the Directors.



Norman A. Seckold
Chairman

Sydney, 26 February 2026

For personal use only



Independent Auditor's Review Report

To the shareholders of Alpha HPA Limited

Report on the Interim Financial Report

Conclusion

We have reviewed the accompanying **Interim Financial Report** of Alpha HPA Limited.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the Interim Financial Report of Alpha HPA Limited does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the **Group's** financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
- complying with *Australian Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

The **Interim Financial Report** comprises:

- Condensed consolidated interim statement of financial position as at 31 December 2025
- Condensed consolidated interim statement of profit or loss and other comprehensive income, Condensed consolidated interim statement of changes in equity and Condensed consolidated interim statement of cash flows for the half-year ended on that date
- Notes 1 to 15 including selected explanatory notes
- The Directors' Declaration.

The **Group** comprises Alpha HPA Limited (the Company) and the entities it controlled at the half year's end or from time to time during the half-year.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the *Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with these requirements.



Responsibilities of the Directors for the Interim Financial Report

The Directors of the Company are responsible for:

- the preparation of the Interim Financial Report that gives a true and fair view in accordance with *Australian Accounting Standards* and the *Corporations Act 2001*
- such internal control as the Directors determine is necessary to enable the preparation of the Interim Financial Report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Review of the Interim Financial Report

Our responsibility is to express a conclusion on the Interim Financial Report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the Interim Financial Report does not comply with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with *Australian Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of an Interim Financial Report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with *Australian Auditing Standards* and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

KPMG

Adam Twemlow
Partner

Brisbane
26 February 2026

For personal use only

Corporate Information

ABN 79 106 879 690

Directors

Norman Seckold – Executive Chairman
Robert Williamson – Managing Director
Rimas Kairaitis – Executive Director and Chief Commercial Officer
Dr Regan Crooks – Non-Executive Director
Annie Liu – Non-Executive Director
Marghanita Johnson – Non-Executive Director
Anthony Sgro – Non-Executive Director

Company Secretary

Richard Edwards

Registered Office

Level 2, 66 Hunter Street
Sydney NSW 2000
Australia

Brisbane Office

341 Thynne Road
Morningside QLD 4170
Australia

HPA First Project

53 Reid Rd
Yarwun QLD 4694
Australia

Auditors

KPMG
Level 11, Heritage Lanes
80 Ann Street
Brisbane QLD 4000

Share Registry

Computershare Investor Services Pty Limited
Level 4, 44 Martin Place
Sydney NSW 2000

For personal use only